Two rare disease-associated Tyk2 variants are catalytically impaired but signaling competent

Journal of Immunology

Volumn 190, Issue 5, 2013, Pages 2335-2344

  Li, Zhi ^a,b   Gakovic, Milica ^a,b   Ragimbeau, Josiane ^a,b   Eloranta, Maija Leena ^c   Rönnblom, Lars ^c   Michel, Frédérique ^a,b   Pellegrini, Sandra ^a,b  

^a INSTITUT PASTEUR   (France)

^b CNRS   (France)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 6; ISOLEUCINE; JANUS KINASE 1; JANUS KINASE 2; PROTEIN KINASE TYK2; SERINE; STAT PROTEIN; STAT1 PROTEIN; STAT2 PROTEIN;

AMINO ACID SUBSTITUTION; ARTICLE; AUTOIMMUNE DISEASE; AUTOPHOSPHORYLATION; CATALYSIS; CONTROLLED STUDY; CROHN DISEASE; CYTOKINE RELEASE; ENDOMETRIOSIS; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME SUBSTRATE; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN CELL; INSULIN DEPENDENT DIABETES MELLITUS; MULTIPLE SCLEROSIS; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PSORIASIS; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS;

ALLELES; AMINO ACID SEQUENCE; AUTOIMMUNE DISEASES; B-LYMPHOCYTES; CELL LINE, TRANSFORMED; GENE EXPRESSION; GENETIC PREDISPOSITION TO DISEASE; GENETIC VECTORS; HERPESVIRUS 4, HUMAN; HUMANS; INTERFERON TYPE I; INTERLEUKIN-10; INTERLEUKIN-6; JANUS KINASE 1; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PLASMIDS; POLYMORPHISM, SINGLE NUCLEOTIDE; SIGNAL TRANSDUCTION; TRANSFECTION; TYK2 KINASE;

EID: 84874260872     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1203118     Document Type: Article

References (56)

1. Velazquez, L., M. Fellous, G. R. Stark, and S. Pellegrini. 1992. A protein tyrosine kinase in the interferon a/b signaling pathway. Cell 70: 313-322.
2. Karaghiosoff, M., H. Neubauer, C. Lassnig, P. Kovarik, H. Schindler, H. Pircher, B. McCoy, C. Bogdan, T. Decker, G. Brem, et al. 2000. Partial impairment of cytokine responses in Tyk2-deficient mice. Immunity 13: 549-560.
3. Shimoda, K., K. Kato, K. Aoki, T. Matsuda, A. Miyamoto, M. Shibamori, M. Yamashita, A. Numata, K. Takase, S. Kobayashi, et al. 2000. Tyk2 plays a restricted role in IFN alpha signaling, although it is required for IL-12- mediated T cell function. Immunity 13: 561-571.
4. Minegishi, Y., M. Saito, T. Morio, K. Watanabe, K. Agematsu, S. Tsuchiya, H. Takada, T. Hara, N. Kawamura, T. Ariga, et al. 2006. Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity 25: 745-755.
5. Kilic, S. S., M. Hacimustafaoglu, S. Boisson-Dupuis, A. Y. Kreins, A. V. Grant, L. Abel, and J. L. Casanova. 2012. A patient with tyrosine kinase 2 deficiency without hyper-IgE syndrome. J. Pediatr. 160: 1055-1057.
6. Shaw, M. H., V. Boyartchuk, S. Wong, M. Karaghiosoff, J. Ragimbeau, S. Pellegrini, M. Muller, W. F. Dietrich, and G. S. Yap. 2003. A natural mutation in the Tyk2 pseudokinase domain underlies altered susceptibility of B10.Q/J mice to infection and autoimmunity. Proc. Natl. Acad. Sci. USA 100: 11594-11599.
7. Shaw, M. H., G. J. Freeman, M. F. Scott, B. A. Fox, D. J. Bzik, Y. Belkaid, and G. S. Yap. 2006. Tyk2 negatively regulates adaptive Th1 immunity by mediating IL-10 signaling and promoting IFN-gamma-dependent IL-10 reactivation. J. Immunol. 176: 7263-7271.
8. Spach, K. M., R. Noubade, B. McElvany, W. F. Hickey, E. P. Blankenhorn, and C. Teuscher. 2009. A single nucleotide polymorphism in Tyk2 controls susceptibility to experimental allergic encephalomyelitis. J. Immunol. 182: 7776-7783.
9. Strobl, B., D. Stoiber, V. Sexl, and M. Mueller. 2011. Tyrosine kinase 2 (TYK2) in cytokine signalling and host immunity. Front. Biosci. 16: 3214-3232.
10. Stoiber, D., B. Kovacic, C. Schuster, C. Schellack, M. Karaghiosoff, R. Kreibich, E. Weisz, M. Artwohl, O. C. Kleine, M. Muller, et al. 2004. TYK2 is a key regulator of the surveillance of B lymphoid tumors. J. Clin. Invest. 114: 1650-1658.
11. Cunninghame Graham, D. S., M. Akil, and T. J. Vyse. 2007. Association of polymorphisms across the tyrosine kinase gene, TYK2 in UK SLE families. Rheumatology (Oxford) 46: 927-930.
12. Hellquist, A., T. M. Järvinen, S. Koskenmies, M. Zucchelli, C. Orsmark-Pietras, L. Berglind, J. Panelius, T. Hasan, H. Julkunen, M. D'Amato, et al. 2009. Evidence for genetic association and interaction between the TYK2 and IRF5 genes in systemic lupus erythematosus. J. Rheumatol. 36: 1631-1638.
13. Sigurdsson, S., G. Nordmark, H. H. Göring, K. Lindroos, A. C. Wiman, G. Sturfelt, A. Jönsen, S. Rantapää-Dahlqvist, B. Möller, J. Kere, et al. 2005. Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. Am. J. Hum. Genet. 76: 528-537.
14. Suarez-Gestal, M., M. Calaza, E. Endreffy, R. Pullmann, J. Ordi-Ros, G. D. Sebastiani, S. Ruzickova, M. Jose Santos, C. Papasteriades, M. Marchini, et al; European Consortium of SLE DNA Collections. 2009. Replication of recently identified systemic lupus erythematosus genetic associations: a casecontrol study. Arthritis Res. Ther. 11: R69.
15. Ban, M., A. Goris, A. R. Lorentzen, A. Baker, T. Mihalova, G. Ingram, D. R. Booth, R. N. Heard, G. J. Stewart, E. Bogaert, et al; Wellcome Trust Case- Control Consortium (WTCCC). 2009. Replication analysis identifies TYK2 as a multiple sclerosis susceptibility factor. Eur. J. Hum. Genet. 17: 1309-1313.
16. Couturier, N., F. Bucciarelli, R. N. Nurtdinov, M. Debouverie, C. Lebrun-Frenay, G. Defer, T. Moreau, C. Confavreux, S. Vukusic, I. Cournu-Rebeix, et al. 2011. Tyrosine kinase 2 variant influences T lymphocyte polarization and multiple sclerosis susceptibility. Brain 134: 693-703.
17. Dyment, D. A., M. Z. Cader, M. J. Chao, M. R. Lincoln, K. M. Morrison, G. Disanto, J. M. Morahan, G. C. De Luca, A. D. Sadovnick, P. Lepage, et al. 2012. Exome sequencing identifies a novel multiple sclerosis susceptibility variant in the TYK2 gene. Neurology 79: 406-411.
18. Johnson, B. A., J. Wang, E. M. Taylor, S. J. Caillier, J. Herbert, O. A. Khan, A. H. Cross, P. L. De Jager, P. A. Gourraud, B. C. Cree, et al. 2010. Multiple sclerosis susceptibility alleles in African Americans. Genes Immun. 11: 343-350.
19. Mero, I. L., A. R. Lorentzen, M. Ban, C. Smestad, E. G. Celius, J. H. Aarseth, K. M. Myhr, J. Link, J. Hillert, T. Olsson, et al. 2010. A rare variant of the TYK2 gene is confirmed to be associated with multiple sclerosis. Eur. J. Hum. Genet. 18: 502-504.
20. Franke, A., D. P. McGovern, J. C. Barrett, K. Wang, G. L. Radford-Smith, T. Ahmad, C. W. Lees, T. Balschun, J. Lee, R. Roberts, et al. 2010. Genomewide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat. Genet. 42: 1118-1125.
21. Sato, K., M. Shiota, S. Fukuda, E. Iwamoto, H. Machida, T. Inamine, S. Kondo, K. Yanagihara, H. Isomoto, Y. Mizuta, et al. 2009. Strong evidence of a combination polymorphism of the tyrosine kinase 2 gene and the signal transducer and activator of transcription 3 gene as a DNA-based biomarker for susceptibility to Crohn's disease in the Japanese population. J. Clin. Immunol. 29: 815-825.
22. Wang, K., H. Zhang, S. Kugathasan, V. Annese, J. P. Bradfield, R. K. Russell, P. M. Sleiman, M. Imielinski, J. Glessner, C. Hou, et al. 2009. Diverse genomewide association studies associate the IL12/IL23 pathway with Crohn Disease. Am. J. Hum. Genet. 84: 399-405.
23. Strange, A., F. Capon, C. C. Spencer, J. Knight, M. E. Weale, M. H. Allen, A. Barton, G. Band, C. Bellenguez, J. G. Bergboer, et al; Genetic Analysis of Psoriasis Consortium & the Wellcome Trust Case Control Consortium 2. 2010. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat. Genet. 42: 985-990.
24. Wallace, C., D. J. Smyth, M. Maisuria-Armer, N. M. Walker, J. A. Todd, and D. G. Clayton. 2010. The imprinted DLK1-MEG3 gene region on chromosome 14q32.2 alters susceptibility to type 1 diabetes. Nat. Genet. 42: 68-71.
25. Peluso, C., D. M. Christofolini, C. S. Goldman, F. A. Mafra, V. Cavalcanti, C. P. Barbosa, and B. Bianco. 2012. TYK2 rs34536443 polymorphism is associated with a decreased susceptibility to endometriosis-related infertility. Hum. Immunol. 74: 93-97.
26. Liu, J. Z., M. A. Almarri, D. J. Gaffney, G. F. Mells, L. Jostins, H. J. Cordell, S. J. Ducker, D. B. Day, M. A. Heneghan, J. M. Neuberger, et al UK Primary Biliary Cirrhosis (PBC) Consortium; Wellcome Trust Case Control Consortium 3. 2012. Dense fine-mapping study identifies new susceptibility loci for primary biliary cirrhosis. Nat. Genet. 44: 1137-1141.
27. Kaminker, J. S., Y. Zhang, A. Waugh, P. M. Haverty, B. Peters, D. Sebisanovic, J. Stinson, W. F. Forrest, J. F. Bazan, S. Seshagiri, and Z. Zhang. 2007. Distinguishing cancer-associated missense mutations from common polymorphisms. Cancer Res. 67: 465-473.
28. Tomasson, M. H., Z. Xiang, R. Walgren, Y. Zhao, Y. Kasai, T. Miner, R. E. Ries, O. Lubman, D. H. Fremont, M. D. McLellan, et al. 2008. Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia. Blood 111: 4797-4808.
29. Velazquez, L., K. E. Mogensen, G. Barbieri, M. Fellous, G. Uzé, and S. Pellegrini. 1995. Distinct domains of the protein tyrosine kinase tyk2 required for binding of interferon-alpha/beta and for signal transduction. J. Biol. Chem. 270: 3327-3334.
30. Gauzzi, M. C., L. Velazquez, R. McKendry, K. E. Mogensen, M. Fellous, and S. Pellegrini. 1996. Interferon-alpha-dependent activation of Tyk2 requires phosphorylation of positive regulatory tyrosines by another kinase. J. Biol. Chem. 271: 20494-20500.
31. Richter, M. F., G. Duménil, G. Uzé, M. Fellous, and S. Pellegrini. 1998. Specific contribution of Tyk2 JH regions to the binding and the expression of the interferon alpha/beta receptor component IFNAR1. J. Biol. Chem. 273: 24723-24729.
32. Ragimbeau, J., E. Dondi, A. Alcover, P. Eid, G. Uzé, and S. Pellegrini. 2003. The tyrosine kinase Tyk2 controls IFNAR1 cell surface expression. EMBO J. 22: 537-547.
33. Gakovic, M., J. Ragimbeau, V. Francois, S. N. Constantinescu, and S. Pellegrini. 2008. The Stat3-activating Tyk2 V678F mutant does not up-regulate signaling through the type I interferon receptor but confers ligand hypersensitivity to a homodimeric receptor. J. Biol. Chem. 283: 18522-18529.
34. Marijanovic, Z., J. Ragimbeau, K. G. Kumar, S. Y. Fuchs, and S. Pellegrini. 2006. TYK2 activity promotes ligand-induced IFNAR1 proteolysis. Biochem. J. 397: 31-38.
35. Miyauchi, K., E. Urano, H. Yoshiyama, and J. Komano. 2011. Cytokine signatures of transformed B cells with distinct Epstein-Barr virus latencies as a potential diagnostic tool for B cell lymphoma. Cancer Sci. 102: 1236-1241.
36. Briscoe, J., N. C. Rogers, B. A. Witthuhn, D. Watling, A. G. Harpur, A. F. Wilks, G. R. Stark, J. N. Ihle, and I. M. Kerr. 1996. Kinase-negative mutants of JAK1 can sustain interferon-gamma-inducible gene expression but not an antiviral state. EMBO J. 15: 799-809.
37. Haan, S., C. Margue, A. Engrand, C. Rolvering, H. Schmitz-Van de Leur, P. C. Heinrich, I. Behrmann, and C. Haan. 2008. Dual role of the Jak1 FERM and kinase domains in cytokine receptor binding and in stimulation-dependent Jak activation. J. Immunol. 180: 998-1007.
38. Zhang, X., J. Gureasko, K. Shen, P. A. Cole, and J. Kuriyan. 2006. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125: 1137-1149.
39. Haan, C., D. C. Kroy, S. Wüller, U. Sommer, T. Nöcker, C. Rolvering, I. Behrmann, P. C. Heinrich, and S. Haan. 2009. An unusual insertion in Jak2 is crucial for kinase activity and differentially affects cytokine responses. J. Immunol. 182: 2969-2977.
40. Cameron, A. J., C. Escribano, A. T. Saurin, B. Kostelecky, and P. J. Parker. 2009. PKC maturation is promoted by nucleotide pocket occupation independently of intrinsic kinase activity. Nat. Struct. Mol. Biol. 16: 624-630.
41. Kornev, A. P., S. S. Taylor, and L. F. Ten Eyck. 2008. A helix scaffold for the assembly of active protein kinases. Proc. Natl. Acad. Sci. USA 105: 14377-14382.
42. Chrencik, J. E., A. Patny, I. K. Leung, B. Korniski, T. L. Emmons, T. Hall, R. A. Weinberg, J. A. Gormley, J. M. Williams, J. E. Day, et al. 2010. Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6. J. Mol. Biol. 400: 413-433.
43. Haan, C., I. Behrmann, and S. Haan. 2010. Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinases. J. Cell. Mol. Med. 14: 504-527.
44. Tsui, V., P. Gibbons, M. Ultsch, K. Mortara, C. Chang, W. Blair, R. Pulk, M. Stanley, M. Starovasnik, D. Williams, et al. 2011. A new regulatory switch in a JAK protein kinase. Proteins 79: 393-401.
45. Andraos, R., Z. Qian, D. Bonenfant, J. Rubert, E. Vangrevelinghe, C. Scheufler, F. Marque, C. H. Régnier, A. De Pover, H. Ryckelynck, et al. 2012. Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent. Cancer Discov 2: 512-523.
46. Yeh, T. C., E. Dondi, G. Uze, and S. Pellegrini. 2000. A dual role for the kinaselike domain of the tyrosine kinase Tyk2 in interferon-alpha signaling. Proc. Natl. Acad. Sci. USA 97: 8991-8996.
47. Chen, M., A. Cheng, F. Candotti, Y. J. Zhou, A. Hymel, A. Fasth, L. D. Notarangelo, and J. J. O'Shea. 2000. Complex effects of naturally occurring mutations in the JAK3 pseudokinase domain: evidence for interactions between the kinase and pseudokinase domains. Mol. Cell. Biol. 20: 947-956.
48. Bandaranayake, R. M., D. Ungureanu, Y. Shan, D. E. Shaw, O. Silvennoinen, and S. R. Hubbard. 2012. Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F. Nat. Struct. Mol. Biol. 19: 754-759.
49. Dusa, A., C. Mouton, C. Pecquet, M. Herman, and S. N. Constantinescu. 2010. JAK2 V617F constitutive activation requires JH2 residue F595: a pseudokinase domain target for specific inhibitors. PLoS ONE 5: e11157.
50. Yang, J., L. F. Ten Eyck, N. H. Xuong, and S. S. Taylor. 2004. Crystal structure of a cAMP-dependent protein kinase mutant at 1.26A: new insights into the catalytic mechanism. J. Mol. Biol. 336: 473-487.
51. Babon, J. J., N. J. Kershaw, J. M. Murphy, L. N. Varghese, A. Laktyushin, S. N. Young, I. S. Lucet, R. S. Norton, and N. A. Nicola. 2012. Suppression of cytokine signaling by SOCS3: characterization of the mode of inhibition and the basis of its specificity. Immunity 36: 239-250.
52. Gough, D. J., N. L. Messina, C. J. Clarke, R. W. Johnstone, and D. E. Levy. 2012. Constitutive type I interferon modulates homeostatic balance through tonic signaling. Immunity 36: 166-174.
53. Prchal-Murphy, M., C. Semper, C. Lassnig, B. Wallner, C. Gausterer, I. Teppner- Klymiuk, J. Kobolak, S. Müller, T. Kolbe, M. Karaghiosoff, et al. 2012. TYK2 kinase activity is required for functional type I interferon responses in vivo. PLoS ONE 7: e39141.
54. Kyogoku, C., A. Morinobu, K. Nishimura, D. Sugiyama, H. Hashimoto, Y. Tokano, T. Mimori, C. Terao, F. Matsuda, T. Kuno, and S. Kumagai. 2009. Lack of association between tyrosine kinase 2 (TYK2) gene polymorphisms and susceptibility to SLE in a Japanese population. Mod. Rheumatol. 19: 401-406.
55. Li, P., Y. K. Chang, K. W. Shek, and Y. L. Lau. 2011. Lack of association of TYK2 gene polymorphisms in Chinese patients with systemic lupus erythematosus. J. Rheumatol. 38: 177-178.
56. Eyre, S., J. Bowes, D. Diogo, A. Lee, A. Barton, P. Martin, A. Zhernakova, E. Stahl, S. Viatte, K. McAllister, et al. 2012. High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. Nat. Genet. 44: 1336-1340.